Background In patients with acute myocardial infarction receiving potent antiplatelet therapy,
the bleeding risk remains high during the maintenance phase. We sought data on a uniform …

Background: Inflammatory responses play a critical role in left ventricular remodeling after
myocardial infarction (MI). Tolerogenic dendritic cells (tDCs) can modulate immune …

Background Myocardial infarction with nonobstructive coronary arteries (MINOCA) is a
heterogeneous disease entity. Its prognosis and predictor of mortality remain unclear. This …

Aims In patients with acute myocardial infarction (MI) and multivessel coronary artery
disease, percutaneous coronary intervention (PCI) of non-infarct-related artery reduces …

Aims The effect of fibrate treatment on cardiovascular risk is inconsistent. This meta-analysis
aimed to assess the effect of fibrates on major adverse cardiovascular outcome (MACE) …

Objectives The aim of this study was to examine the impact of intravascular ultrasound
(IVUS)–guided percutaneous coronary intervention (PCI) on long-term clinical outcomes in …

Aims We investigated the association between diabetes duration and the extent and severity
of coronary artery disease (CAD) as well as long-term clinical outcomes using coronary …

Aims Dual-antiplatelet therapy (DAPT) with aspirin and a potent P2Y12 inhibitor is the
standard treatment for patients with acute coronary syndrome (ACS) undergoing …

Objective β-blockers are the standard treatment for myocardial infarction (MI) based on
evidence from the pre-thrombolytic era. The aim of this study was to examine the effect of β …

Background The no-reflow phenomenon is a potential complication of primary percutaneous
coronary intervention (PCI). Predictors of the no-reflow phenomenon and the impact on long …